

The Board of Pharmacy has received notice of the following product withdrawal. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

CSL Behring has instituted a withdrawal of:

Subject: Immune Globulin Intravenous (Human)

Privigen® 10% (10g/100mL)

Lot Number: P100287723

NDC Number: 44206-0437-10

The table below indicates the impacted lot of PRIVIGEN that was shipped from CSL Behring beginning in July 2021:

Privigen® 10% (10g/100mL)	
NDC: 44206-0437-10	
LOT	EXPIRY DATE
P100287723	17-NOV-2023

CSL Behring has instituted a withdrawal of one (1) lot of PRIVIGEN at the hospital/pharmacy level due to an increased frequency of reports of hypersensitivity reactions during or after administration. Hypersensitivity reactions are a known risk with Intravenous Immune Globulin (IVIG) products.